๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Avalyn Pharma Inc. (AVLN)
NASDAQ: AVLN ยท Real-Time Price ยท USD
28.82
+0.90 (3.22%)
Nov 18, 2026, 1:01 PM EST - Market open
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

Inhaled delivery aims to improve tolerability and broaden treatment access in pulmonary fibrosis. AP01 and AP03 readouts are expected in H2 2027, while AP02 proof-of-concept data are expected late 2027; subsequent development will depend on results and FDA discussions.

Roger Song
Senior Equity Research Analyst, Jefferies

Welcome.

Lyn Baranowski
CEO, Avalyn Pharma

Thank you so much. Nice to be here.

Roger Song
Senior Equity Research Analyst, Jefferies

Awesome. Lyn, why not you give us a one or two-minute overview of Avalyn, because I think 2027 is very transformative for you, and then why you are excited.

Lyn Baranowski
CEO, Avalyn Pharma

Yeah. Thanks so much, Roger. Hi, everybody. Thanks for coming today. Avalyn Pharma is a company focused on a clinical-stage portfolio of assets targeting pulmonary fibrosis. It is one of the rare, very deadly diseases in the lung space that we think is in desperate need of better and new options. What I mean by that, survival with this disease is about three to five years. There are a few drugs approved, but it is only about 10% of patients over the course of a year that are diagnosed with this deadly disease are able to access any of those existing oral medicines. Fundamentally, because the drugs that exist are almost impossible to tolerate, they add very difficult GI side effects on top of the already very difficult symptoms of the disease.

For that reason, patients that might try them often will cycle off therapy within a few months. What we are doing at Avalyn is taking those same drugs that exist, the two that have been around for about 10 years, they are called pirfenidone and nintedanib. We think that rather than delivering them orally, it is much more sensible to deliver them to the lung directly with an inhalation. When we do that, because we are focusing the drug in the lung, we can drop the dose considerably as compared to the oral version. Pirfenidone, as an example, goes from 2,400 mgs a day to 200, but we actually had better exposure in the lung than the oral. We think that is translating in the clinical data to better efficacy with this approach.

And at the same time, when you avoid your systemic exposure by focusing it in the lung and drop the dose, your systemic exposure is much lower than you would have with the oral, and we think that is now what is resolving and largely addressing the tolerability issues that are the rate limiters to adoption. Our view is it is a sensible approach, high probability of success, given that we are working with drugs that we know work, and delivering them in a better way that makes it accessible for patients. We think fundamentally the approach will really change the product profiles for the better, and fundamentally allow us now to access the majority of patients in the marketplace that are just not being treated today. We have a clinical-stage portfolio, as I mentioned.

We have a drug, the inhaled pirfenidone, AP01, that completed an enrollment in a large global phase II-B study over the summer. It is a 52-week study, so we will have data back from that in the second half of next year. We also have a phase II ongoing for our inhaled nintedanib, that is AP02, another global phase II study. That one is more of a proof of concept, 12-week study. We think we will have data back from that program late in 2027. Last week, we announced that we have advanced our combination product, that is called AP03, and that is a fixed-dose combo of those two monotherapy ingredients.

We advanced that into a phase I study, and so that phase I is now starting up, and we think we will have that one fully reading out again in the second half of next year. Roger, to your point, it is going to be a really busy second half of 2027, but we are just so excited for what we hopefully can do to help these patients.

Roger Song
Senior Equity Research Analyst, Jefferies

Excellent. Okay, that is a great overview. Lyn, we have a lot to cover today, but probably the focus will be AP01 and AP02.

Lyn Baranowski
CEO, Avalyn Pharma

Yeah.

Roger Song
Senior Equity Research Analyst, Jefferies

AP03 is definitely very interesting in a bit earlier stage. For AP01, the MIST phase IIb, that is statistical power for efficacy. Just tell us what is the goal here? In terms of you want to improve the efficacy compared to oral version, or how likely you're going to achieve that? If you achieve that, would that change your regulatory perspective in terms of the next step in approval?

Lyn Baranowski
CEO, Avalyn Pharma

Yeah, great question. Thank you, Roger. I will say that when I joined the company, I started doing some market research with doctors and patients. I was actually shocked to understand how much improving tolerability alone matters. For us, when we think about our base case in a product presentation, we think about just improving tolerability as compared to the existing orals. We think any change in tolerability can really be significant in terms of commercial potential. Doug maybe can speak more to that. We have a recent example of that. JASCAYD is launching now. It's a drug from BI, just a slight improvement in tolerability over the oral nintedanib, and they're really doing great commercially. So tolerability advantage is really meaningful and important in this market.

The clinical data that we have suggests that we can not only improve tolerability, but that we can also improve the efficacy in a very substantial way. If we can do both of those, we think of this as being a bit of a game changer in this field. Should really allow patients now to be treated much better over a much longer term horizon. We have data in patients that have been in the program for beyond five years, which is remarkable given the survival and the disease. It just speaks to what we might be able to do here to actually change the course of the diagnosis and perhaps extend lives, and that obviously is going to add commercial value as well. So both are important, but just a tolerability advantage will add a lot of value. In terms of regulatory pathway-

Roger Song
Senior Equity Research Analyst, Jefferies

Yep.

Lyn Baranowski
CEO, Avalyn Pharma

We're assuming that MIST, which is our AP01 phase IIb, has been designed as a dose-ranging study, but really designed with pivotal in mind. What I mean by that, it's more than 90% power to detect a signal for the high dose versus placebo. It's one year in duration. It's 398 patients. So our view is that from a conservative base case perspective, we expect that we'll likely have another phase III to do after that for approval. There could be an upside to that plan. We'll certainly talk to the agency about MIST and whether or not there might be upsides based on data. I think the most conservative plan, the one that we're assuming as our base case, is that we'll have another phase III to do after this for approval.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it. Yeah. We know the oral ones also works. If you achieve parity on the efficacy, that is probably the base case.

Lyn Baranowski
CEO, Avalyn Pharma

Yep.

Roger Song
Senior Equity Research Analyst, Jefferies

If you get higher efficacy, you will strive for maybe a little bit different or accelerated regulatory pathway. What could be the potential? You can run another phase III, but in different indication, IPF. Sorry, we didn't mention the MIST in PPF. How likely are you going to run a phase III in IPF and get a label for both? Do we know when you talk with, I think that's a possibility, but

Lyn Baranowski
CEO, Avalyn Pharma

Yeah.

Roger Song
Senior Equity Research Analyst, Jefferies

Have you any numbers FDA really looking for? Like, okay, you have a 10%-20% higher than the standard of care, and we can look at this, because it's a placebo, and it's a cross-trial comparison.

Lyn Baranowski
CEO, Avalyn Pharma

Yeah, it's a good question. I don't think we know strictly what the numbers that they're looking for. I think in our minds, it's going to be a data issue. We'll see what the data suggests, and then see what the right conversation is to have with the agency. As I said, I think that equivalent efficacy to the orals, but a change on tolerability is certainly a really viable opportunity, again, because most patients can't stay on these medicines because of the tolerability profile. But we'll have to talk to the agency about that. In terms of your question about IPF and PPF, it might be helpful for the audience just to speak for just a minute about what those two diseases are. So I trust, I'm guessing most people in the room have heard of IPF. It's idiopathic, meaning we don't know the reason for the disease onset.

The difference between it and PPF is not idiopathic. PPF is driven often by an underlying diagnosis. There is kind of a universe of possible underlying diagnoses. The ones that we see most commonly in the clinic are patients that have systemic autoimmune diseases. They go on to develop interstitial lung disease because of those autoimmune diseases, like rheumatoid arthritis. When the interstitial lung disease sets in, they get an upregulation in inflammation that leads to downstream fibrosis. That is now called PPF. The FDA has asked us to distinguish clinically between studying IPF and PPF. But the pathophysiology of the two diseases is the same. Fibrosis is fibrosis.

We have learned how to study PPF correctly, and there are some nuances to how we do that, Roger, which we can happily talk about if that is helpful. It involves a set of inclusion criteria that BI developed in their nintedanib program. We call it the INBUILD criteria. When we use those criteria in PPF, we are essentially picking patients to study who are analogous to IPF in terms of their rate of downward decline in lung function.

Roger Song
Senior Equity Research Analyst, Jefferies

Okay.

Lyn Baranowski
CEO, Avalyn Pharma

When we use those criteria, we have generated now data that is really superimposable across the two populations in IPF and PPF, both in the nintedanib program and in now the nintedanib program. We are using those same criteria in our study. To your question, I think to the extent that we are going to do a phase III after MIST, we would prefer to do it in IPF so that perhaps we can come to market with both indications. But again, that is going to be a discussion with the agency. Happy to update you on that conversation once we have it.

Roger Song
Senior Equity Research Analyst, Jefferies

Excellent. Okay. You definitely mentioned this in the trial design and the INBUILD criteria. I know you have a good team to design the trial. Just how much the base I believe you will release the baseline blinded data early next year as well. What are the key elements of the baseline characteristics we should pay attention, and that will potentially impact the final outcome? I am thinking about prior therapy, nintedanib versus the JASCAYD, and some of the other baseline FVC. What are the key components we should pay attention, and how this will impact the outcome?

Lyn Baranowski
CEO, Avalyn Pharma

Yeah, it's a great question. Roger mentioned we have a great team. I should kind of give them a shout-out. Most of our clinical team came from Boehringer Ingelheim. They developed the oral nintedanib there, and then the nintedanib as well. Those are the folks that work for us. I would say to you that as we put this program together, actually all the programs, we were really informed by kind of the experience that that team had in how to develop these drugs correctly, how to do them with the right sites, how to pick the right patients. In terms of thinking about baseline characteristics, you're right, we will aim to release that, assuming the abstract is accepted in the first half of the year next year. You'll see that likely before the data.

But I would say that it's probably going to be somewhat comparable to the nintedanib PPF data. Their pivotal trial in PPF is called FIBRONEER, and I would say it's probably going to be similar in that regard. You're going to want to be looking for the number of patients on background therapies. You're going to want to be looking for what kinds of underlying diagnoses the patient population had. We always look, and we're careful to think about the geographic dispersity too. We want to make sure that we're studying patients, in this case, in the U.S. and Europe and in other places that we're doing the study, and to make sure it's kind of well-balanced in that regard.

Roger Song
Senior Equity Research Analyst, Jefferies

Okay. When you say well-balanced, if it's not that as similar to the FIBRONEER, would that be a materially impact outcome, or how should we think about when we see the data? Or you just think the base case is going to be very balanced?

Lyn Baranowski
CEO, Avalyn Pharma

Yeah, I think we just are focused on quality trials and quality execution and operations. I don't know that it would actually impact the outcome. I just think that's the characteristic of a well-run trial, is to see a nice geographic distribution. It was interesting, I mean, just since you're asking, to spend a minute on this. Nintedanib's pivotal study was the first time that we've seen an oral drug, nintedanib, used on top of background therapy, pirfenidone and nintedanib. That's what we're working with. Everyone else in the space that's doing work with novel mechanisms is studying their novel mechanisms on top of background therapy. It was interesting to see that nintedanib data.

What you see, you can look at the background group, so you can look at the group that had no background, the group that had nintedanib background, pirfenidone background, and you actually see an equal treatment effect of nintedanib, regardless of what the background was. After that, we then got data from the TYVASO program, the treprostinil. It is an inhaled nebulized therapy in the same diseases, same backgrounds. If you look at that data, treprostinil was actually not effective, not stat sig in either phase III trial in IPF in patients that were not on background. It was only effective on top of patients that were on pirfenidone and nintedanib, and the treatment effect was significantly larger for patients that were on background. Just some interesting data.

But what it tells us fundamentally is that based on those two trials, it does not appear that allowing background therapy is going to limit your treatment effect. It may only actually improve it. The reason being that patients now coming into these trials, and you can see this on background characteristics, based on characteristics, patients coming into these trials that are on background are often older, sicker, more frail, more in need of therapies. So, you can see the decline that is more profound in the placebo groups in both studies.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it.

Lyn Baranowski
CEO, Avalyn Pharma

Is that helpful?

Roger Song
Senior Equity Research Analyst, Jefferies

Yeah, that's very helpful. This is the inhaled version of pirfenidone and nintedanib at the AP02. How should we think about the access from the payer side, and what's been the discussion going on? We know that JASCAYD is definitely starting to use it in that case, but also still limited use case yet.

Doug Carlson
CFO and Chief Business Officer, Avalyn Pharma

Yeah. It's something very timely we just set up here at board last week. At the moment, pulmonary fibrosis is not a top 100 disease for payers. Of course, that could evolve over time. JASCAYD is quite an interesting case study. That's the oral nintedanib, which was approved around this time last year, launched by Boehringer Ingelheim. That product was priced at a premium to the historical prices of the oral branded products. It's about $200,000 per annual cost per patient. That product is currently doing an annualized run rate of about over $2 billion in gross sales. What's happening in the category with a product like that is there's relatively soft step edits. Really, a physician is attesting that a patient has either attempted to try one of the two orals and has not been able to tolerate it.

I think broadly speaking, we would expect this level of step edits, which is in this category where patients are coming onto these medicines, not able to tolerate. You think about the patient pool kind of in thirds. One large group of patients that have attempted the orals, can't tolerate them, are waiting for new medicines. Patients that are naive and very reluctant to attempt an oral, just given the perception of the GI issues, which are real. Then patients that are on medicine that can cycle off. It's really a unique time in pulmonary fibrosis to bring novel medicines to market, and we're seeing that real time with JASCAYD.

Just as a reminder, similar efficacy is the orals, marginally better tolerability with diarrhea being the big liability. With that said, wide adoption. That really speaks to our base case of significantly improving tolerability, where if we show that efficacy is similar as a base case, the upside case, if we're improving efficacy above the orals, we think of that as a kind of a grand slam opportunity for us. Really excited about what's happening in the market.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it.

Lyn Baranowski
CEO, Avalyn Pharma

Can I make one more comment?

Roger Song
Senior Equity Research Analyst, Jefferies

Yeah, sure.

Lyn Baranowski
CEO, Avalyn Pharma

Just about the market, just while we are on the topic? Because I think it is always helpful to remind people of how big an opportunity this can be. What I mean by that is that OFEV is considered a very successful product. It certainly is commercially. It is about a $4 billion drug globally in sales. As Doug said, JASCAYD is off to a great start, $2 billion run rate in its first year. But if you think about just U.S. market for a minute. So, U.S. market alone, there are about 300,000 patients diagnosed today with one of the two forms of pulmonary fibrosis, IPF and PPF.

If you dollarize the market using the lowest brand pricing today, it is $150,000 per patient per year. That is a U.S. market size today, assuming everyone is only on one drug, of $42 billion. Hopefully through that lens, you've now understood how few patients they're reaching because of the tolerability profile. OFEV, great product, $4 billion commercially, but it's a $42 billion market. As Doug said, there's just a lot of value to be unlocked here, a lot of patients that we can treat with better tolerability and hopefully for better efficacy as well.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it. Okay. That's one drug already $42 billion market. How should we think about this polypharmacy? We saw that in many other respiratory disease, and start with some of the rare disease as well. What's the payer feedback, as you probably just had a conversation with them? Do they really allow those kind of co, two dual branded drug, and how think about the overall pricing in this rare disease framework?

Doug Carlson
CFO and Chief Business Officer, Avalyn Pharma

Yeah, and it's one of the benefits of the trial design of MIST, where we have a cohort of patients that will be on the background, either nintedanib or in some cases, JASCAYD, nintedanib, but predominantly nintedanib. Having that data to show the clinical benefit, I think, is important. There's analogous examples, whether it's PAH, where multiple loose combinations of brands are being used together. It's a conversation that payers are open to. Of course, it'll come down to prior authorization, step edits, but we feel very confident that similar to other, whether it's asthma, COPD, PAH, this market's going to transition to more combination uses as more medicines are being able to use in combination. Right now, it's not possible with the tolerability challenges.

Roger Song
Senior Equity Research Analyst, Jefferies

Are they starting to cover some of the dual brands, or it's still kind of early days or very special kind of approval?

Doug Carlson
CFO and Chief Business Officer, Avalyn Pharma

It is a good question. JASCAYD, given the diarrhea liability, if that is used in combination with nintedanib, which they did show in the study, that is exacerbated. Two products with diarrhea combined, of course, it is not surprisingly, that is debilitating. There is limited combination use currently in the pulmonary fibrosis market, but I think we think of ourselves, especially with AP03 on the horizon, as a company that has a very strong strategy to leverage the combination approach going forward.

Lyn Baranowski
CEO, Avalyn Pharma

Yeah, and it is, I think, fundamentally exactly as Doug said, that is what we are all about. Fundamentally, we cannot, as a field, evolve the treatment algorithm in pulmonary fibrosis yet because the orals are so impossible to tolerate. You need to first solve that problem. I think the inhaled delivery does it, and that is going to allow us to step up to combos. We are genuinely enthusiastic. There are other companies in our field doing work with other systemic molecules, novel mechanisms. They are all studying them, by the way, on top of standard of care, which is what we are working with.

We are genuinely hopeful for patients' sake that they will succeed as well, and that hopefully we will be in a situation where we can use loose combos of maybe our drug with one of those systemics as a loose combo for patients, maybe in the future more fixed-dose combos. But it is fundamentally about, again, making them possible to combine. Today, we just cannot combine them in terms of the real world.

Roger Song
Senior Equity Research Analyst, Jefferies

Yeah. Hopefully, future Avalyn will be the background therapy and everyone working on the novel mechanism and then can use on top of you, and then you always.

Lyn Baranowski
CEO, Avalyn Pharma

Yeah. Exactly. That's what we hope.

Roger Song
Senior Equity Research Analyst, Jefferies

Okay, good. On the AP02, as you said, Lyn, it is a proof of concept. It is ex-U.S. How should we think about the U.S. strategy, particularly what's the next step for the AP02?

Lyn Baranowski
CEO, Avalyn Pharma

Yeah, sure. Thanks, Roger. When we talked to the agency about the AP02 program, they asked us to do some additional device compatibility work. Completing that would have slowed our ability to get started with AP02. We were eager to go, so we decided to do that study ex-U.S. They also had some questions about non-clinical tox. We thought we were just in the best position to go ahead and do that study ex-U.S. because no one else had these requests or questions. We went ahead and started the study up ex-U.S. In the meantime, we completed that device compatibility work successfully.

We think that when we have this data package back, again, it's a 12-week proof of concept, that we'll be in a good position to go reengage the agency and have that conversation about the next steps with that program, aiming for phase III. Important to say that in our field, lots of companies do this same pathway, kind of do phase IIs ex-U.S., and then try to come back into the U.S. for phase III, including oral nintedanib. It's been a strategy that's been very successfully employed by many folks in our space before.

Roger Song
Senior Equity Research Analyst, Jefferies

Okay. This is a proof of concept. What would be the target profile you want to achieve for the phase II-A, then you can move into the You say you are aiming phase III. What would be able to enable the next step would be the phase III?

Lyn Baranowski
CEO, Avalyn Pharma

Yeah, sure. The inhaled nintedanib, the AP02 program, Doug mentioned earlier, nintedanib's primary liability is diarrhea. When we did the phase I work, we were looking closely for diarrhea. I am delighted to tell you, and I still get goosebumps when I say it, we did not see any diarrhea in the phase I program. That is, we think, owing to the fact that we are dropping that dose. Oral nintedanib is 150 mgs. We think the right dose with the inhaled is either two or four. So we have between 17 and 26 times less plasma exposure, and we think that is what is giving us now that ability to improve diarrhea. This phase II proof of concept is a 12-week study.

If you look at the curve with oral nintedanib in terms of discontinuations, it is about 50% of patients are going to discontinue that therapy within a few months. Our view is that 12 weeks is really enough to really get a good sense now for what amount of diarrhea we are going to see in that program. That is the primary objective of that 12-week proof of concept. On the efficacy side, we always want to do proper dose ranging to satisfy the FDA. In this study, we are looking at a four mg inhalation and a two.

If you look back historically at the oral nintedanib program, you saw a very clear separation of the doses at between four and six weeks. By 12 weeks with the oral, it was enough. Our view is that really 12 weeks with the inhaled, given that, by the way, we are 27 times higher in lung exposure than the oral, even at that fraction of a dose, we think 12 weeks is going to be enough to observe a difference between the doses and then pick the right dose to get into phase III. That is the objective.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it.

Lyn Baranowski
CEO, Avalyn Pharma

Less diarrhea than the oral, and hopefully at least a separation in the doses so that we can get the right dose into phase III.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it. Okay. I do not see many competitors in the pipeline in terms of the different formulation or different ways to using the same pathway in terms of the background, the orals. Using the nebulizer, I see one is a DPI, maybe one is oral, different form of the pirfenidone. How do you think the nebulizer is the right approach to transform this background pirfenidone and nintedanib?

Lyn Baranowski
CEO, Avalyn Pharma

Yeah, thank you for the question. We actually formulated both. With our nintedanib program, we formulated a dry powder inhaler and a nebulizer. We decided to use the nebulizer for two big reasons. With pirfenidone, which is the AP01 program, the volume of drug prohibits any quick inhaler. The nebulizer is the only game in town. More importantly for the patients, I want you all to see if you can imagine, and I wish we had video, hopefully we will get some video, of what these patients are like. This is not me and you. These are like grandparents who typically have breathlessness. They have a lot of issues with cough. They are quite old, frail. Many of them are on oxygen. We really wanted to think carefully about what the right way to actually allow the patients to dose was.

A dry powder inhaler is a single-dose inhaler. I should say, by the way, this patient population, about 70% of the time, has a symptom of cough as part of their disease. A dry powder inhaler requires a vigorous inhalation. There is no propellant. I do not have one, but it would be like this. I can do that because I have got good inhalation capacity. I only have mild asthma. But a patient with this disease is going to have a hard time doing that. If you are relying on one breath to dose and you have got cough, a dry powder inhaler throws a bunch of dry powder on the back of your throat, and guess what? Makes you cough.

Our view is that it is a little scary clinically to rely on a DPI because you are likely to cough it right back out, not get enough drug on board. The nebulizer, we are using a handheld nebulizer. It is manufactured by PARI, the same device that Insmed uses for ARIKAYCE. It is 510(k) approved. We have a license to it, and importantly, we have exclusivity in it in these molecules. What is great about it is it does not require any kind of special breathing. It kind of customizes itself to each of your breathing capacity. It is just normal tidal breathing. You put the mouthpiece in your mouth, and you breathe in and out normally.

You are going to be relying on time to dose. It is about eight and a half minutes twice a day. You are going to use somewhere between 100 and 200 breaths to dose. Even if you cough once or twice in the beginning, which might happen, you are still going to be able to get enough drug on board to see efficacy. It is really for patients' sake that we want to keep it in that device because we think it is the right way to dose these folks.

Roger Song
Senior Equity Research Analyst, Jefferies

Excellent. Awesome. Thank you so much, Lyn. Thank you so much, Doug. Thank you, everyone.

Lyn Baranowski
CEO, Avalyn Pharma

Thank you.

Doug Carlson
CFO and Chief Business Officer, Avalyn Pharma

Thank you.